Developer docs
API playgroundTry for free, no card

Search company profiles

GlycanAge

Full company profile

uuid0000sf7

Namestring
GlycanAge
Legal namestring
GlycanAge Ltd
Websiteurl
glycanage.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewcastle Upon Tyne, United Kingdom
HQ citystring
Newcastle Upon Tyne
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biological age testing, glycan biomarker analysis, longevity diagnostics, immune age measurement, preventive health testing
Industry1 code
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Biological Age Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct-to-Consumer Biological Age Testing
TypeSubscription Recurring
Description

GlycanAge sells biological age test kits directly to consumers through its e-commerce website. Customers purchase test kits (annual subscription, bi-annual subscription, one-off purchase, or two-test bundle) and receive at-home testing kits with personalized reports and specialist consultations included.

glycanage.com
2Healthcare Provider / Hospital Integration
TypeSubscription Recurring
Description

GlycanAge deploys its biomarker technology into hospital and clinical settings for routine cardiometabolic risk screening. The company validates diagnostic indications and develops lab-developed tests for hospital settings, generating revenue through clinical partnerships and testing services.

therecursive.com
3Research Collaborations
TypeProfessional Services
Description

GlycanAge provides its technology and research capabilities to academic and clinical research institutions studying aging, inflammation, and longevity. Collaborations with institutions like Buck Institute for Research on Aging and Mayo Clinic support scientific advancement while generating revenue.

glycanage.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details4 tiers
1Annual subscription plan with 10% savings
ModelSubscriptionBilling cadenceAnnual
Notes

£342.00 per year (regularly £379.00) - includes ongoing biological age tracking with annual check-ins. Cancel anytime.

glycanage.com
2Bi-annual subscription with 15% savings - ideal for tracking active lifestyle changes
ModelSubscriptionBilling cadenceMulti-year contract
Notes

£323.00 per test (regularly £379.00) - billed per test every 6 months. Cancel anytime.

glycanage.com
3One-off standalone test
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

£379.00 per test - ideal for a standalone check-in to see current biological age.

glycanage.com
4Two-test bundle with 10% savings
ModelUnit PricingBilling cadencePay-as-you-go
Notes

£684.00 for two tests (regularly £758.00) - one-time purchase for before & after approach or sharing with another person.

glycanage.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

GlycanAge provides a glycan-based biological age testing service that measures patterns of glycans attached to immunoglobulin G antibodies through an at-home finger-prick blood test. Results are delivered as personalized biological age reports combined with 1:1 longevity specialist consultations, with three primary service lines: personal-use test kits for consumers, clinical integration for healthcare providers and longevity clinics, and research services for academic institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Therapeutic plasma exchange produces −0.4 years per month reduction in glycan age, the largest among tested interventions (hormone replacement therapy and caloric restriction)
+2 more records
Product overview1 text field

GlycanAge offers a glycan-based biological age testing platform with three primary service lines: personal use (at-home testing with finger-prick blood sample), healthcare provider integration (for clinicians and longevity practices), and research services. The core product is the GlycanAge test, which measures glycans on immunoglobulin G antibodies to estimate biological age and track immune system aging. Results are delivered as personalized reports with 1:1 specialist consultations. The company offers multiple subscription tiers (annual, bi-annual, one-off, bundle) priced at approximately £342-379, and operates across approximately 2,000 clinics in 64 markets.

Product and service2 records
1GlycanAge Biological Age Test (Personal Use)
CategoryDirect-to-consumer biological age diagnostics
Description

At-home biological age testing service for individuals, comprising a finger-prick blood collection kit (four drops of blood on a collection card, returned in a prepaid envelope), a personalized biological age and inflammatory profile report delivered in 3-4 weeks, and a 1:1 longevity specialist consultation to interpret results and recommend lifestyle changes. Designed for health-conscious individuals interested in longevity, biohacking, and personalized preventive healthcare.

2GlycanAge for Healthcare Providers
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-20
Description

Co-organizer of the ISABS conference with GlycanAge's 'Inflammaging in Clinical Practice' satellite event, positioning the company within prestigious medical conference series.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-20
Description

Professional society co-organizing the conference series where GlycanAge hosts its inflammaging satellite event, marking 25 years of inflammaging research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Co-authored landmark study validating glycans as aging biomarkers with investigators from GlycanAge and Buck Institute for Research on Aging, advancing evidence-based TPE protocols through longevity clinics.

4St. Catherine Specialty Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

First hospital deployment of GlycanAge's biomarker technology in Zagreb, integrating glycan biomarkers into routine cardiometabolic risk screening - serving as the flagship hospital integration reference.

therecursive.com
5King Abdulaziz City for Science and Technology
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Saudi Arabia's national research center partnering with GlycanAge to establish a Middle East laboratory for expanding diagnostic capabilities in the region.

forbes.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Fountain Life operates premium longevity clinics offering advanced diagnostics (full-body MRI, blood biomarkers, AI-driven health assessments) and would be a relevant peer given GlycanAge's push to integrate glycan biomarkers into longevity clinic and hospital workflows as an embedded diagnostic layer.

TypeDirect peer
Description

TruDiagnostic offers epigenetic age testing and multi-omic biomarker analysis to both consumers and clinicians, with a strong focus on clinical research partnerships and longevity clinics — closely paralleling GlycanAge's consumer-plus-healthcare-provider model and biological age biomarker positioning.

TypeBroad incumbent
Description

Human Longevity Inc. provides comprehensive whole-genome sequencing, advanced imaging, and full-body diagnostics through premium executive health programs, competing with GlycanAge in the premium longevity diagnostics segment via a much broader (and higher-priced) multi-omics offering aimed at ultra-high-net-worth longevity clients.

TypeDirect peer
Description

InsideTracker provides at-home blood-based biomarker testing with personalized longevity and performance recommendations, offering a comparable D2C subscription model and serving overlapping health-optimization consumers who want measurable biological age and healthspan insights.

TypeDirect peer
Description

ZOE combines at-home blood, microbiome, and continuous glucose testing with personalized nutrition guidance for health-conscious consumers. It targets the same longevity/wellness segment as GlycanAge and competes on integrated biomarker testing plus lifestyle recommendations and 1:1 specialist interpretation.

TypeDirect peer
Description

Tally Health is a D2C biological age testing company offering at-home epigenetic age tests and longevity supplements, directly competing with GlycanAge in the consumer longevity testing category with overlapping target customers (biohackers, health-conscious consumers) and similar subscription pricing models.

TypeDirect peer
Description

Elysium Health developed the Index at-home biological age test measuring cellular health via DNA methylation, and supplements (Basis). It competes directly with GlycanAge in the consumer biological age testing space and shares a similar science-led brand positioning backed by academic researchers.

TypeBroad incumbent
Description

Genentech (Roche) operates large-scale glycobiology and biopharma research programs and represents a broad incumbent in the glycobiology space whose commercial drug pipelines (e.g., glyco-engineered antibodies) demonstrate the broader pharmaceutical potential of IgG glycan science that GlycanAge's biomarker platform is built upon.

TypeDirect peer
Description

Function Health offers comprehensive at-home blood-based health testing (100+ biomarkers) with clinician review, targeting the same health-conscious consumer and longevity-conscious segment as GlycanAge, with a similar premium subscription model and at-home finger-prick collection approach.

TypeEmerging player
Description

Viome provides at-home microbiome and gene expression testing combined with personalized nutrition recommendations, overlapping with GlycanAge's D2C longevity testing and personalization model but using a different biological measurement modality (gut microbiome and mRNA rather than glycan biomarkers).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GlycanAge

Biological Age Diagnosticsglycanage.com

GlycanAge firmographics

Firmographics
Name
GlycanAge
Legal name
GlycanAge Ltd
Website
https://glycanage.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

GlycanAge industry classification

Industry
Product category
Biological Age Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biological age testing
  • Glycan biomarker analysis
  • Longevity diagnostics
  • Immune age measurement
  • Preventive health testing

Where GlycanAge is headquartered

Location

Headquarters

HQ city
Newcastle Upon Tyne
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

GlycanAge business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Direct-to-Consumer Biological Age Testing: GlycanAge sells biological age test kits directly to consumers through its e-commerce website. Customers purchase test kits (annual subscription, bi-annual subscription, one-off purchase, or two-test bundle) and receive at-home testing kits with personalized reports and specialist consultations included.
  2. Healthcare Provider / Hospital Integration: GlycanAge deploys its biomarker technology into hospital and clinical settings for routine cardiometabolic risk screening. The company validates diagnostic indications and develops lab-developed tests for hospital settings, generating revenue through clinical partnerships and testing services.
  3. Research Collaborations: GlycanAge provides its technology and research capabilities to academic and clinical research institutions studying aging, inflammation, and longevity. Collaborations with institutions like Buck Institute for Research on Aging and Mayo Clinic support scientific advancement while generating revenue.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualAnnual subscription plan with 10% savings
SubscriptionMulti-year contractBi-annual subscription with 15% savings - ideal for tracking active lifestyle changes
One time/ perpetual licensePay-as-you-goOne-off standalone test
Unit PricingPay-as-you-goTwo-test bundle with 10% savings

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

GlycanAge product offering

Product offering

Core offering

GlycanAge provides a glycan-based biological age testing service that measures patterns of glycans attached to immunoglobulin G antibodies through an at-home finger-prick blood test. Results are delivered as personalized biological age reports combined with 1:1 longevity specialist consultations, with three primary service lines: personal-use test kits for consumers, clinical integration for healthcare providers and longevity clinics, and research services for academic institutions.

Product overview

GlycanAge offers a glycan-based biological age testing platform with three primary service lines: personal use (at-home testing with finger-prick blood sample), healthcare provider integration (for clinicians and longevity practices), and research services. The core product is the GlycanAge test, which measures glycans on immunoglobulin G antibodies to estimate biological age and track immune system aging. Results are delivered as personalized reports with 1:1 specialist consultations. The company offers multiple subscription tiers (annual, bi-annual, one-off, bundle) priced at approximately £342-379, and operates across approximately 2,000 clinics in 64 markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • GlycanAge Biological Age Test (Personal Use) At-home biological age testing service for individuals, comprising a finger-prick blood collection kit (four drops of blood on a collection card, returned in a prepaid envelope), a personalized biological age and inflammatory profile report delivered in 3-4 weeks, and a 1:1 longevity specialist consultation to interpret results and recommend lifestyle changes. Designed for health-conscious individuals interested in longevity, biohacking, and personalized preventive healthcare.
  • GlycanAge for Healthcare Providers

Quantifiable outcome

  • Therapeutic plasma exchange produces −0.4 years per month reduction in glycan age, the largest among tested interventions (hormone replacement therapy and caloric restriction)
  • +2 more outcomes

Companies that use GlycanAge

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles3 records

GlycanAge technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

GlycanAge partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic and core.

  • Mayo ClinicstrategicStrategic or Co-development Partner · 20 June 2026Co-organizer of the ISABS conference with GlycanAge's 'Inflammaging in Clinical Practice' satellite event, positioning the company within prestigious medical conference series.
  • ISABS (International Society for Applied Biological Sciences)strategicStrategic or Co-development Partner · 20 June 2026Professional society co-organizing the conference series where GlycanAge hosts its inflammaging satellite event, marking 25 years of inflammaging research.
  • Circulate HealthcoreStrategic or Co-development Partner · 19 May 2026Co-authored landmark study validating glycans as aging biomarkers with investigators from GlycanAge and Buck Institute for Research on Aging, advancing evidence-based TPE protocols through longevity clinics.
  • St. Catherine Specialty HospitalcoreStrategic or Co-development Partner · 18 December 2025First hospital deployment of GlycanAge's biomarker technology in Zagreb, integrating glycan biomarkers into routine cardiometabolic risk screening - serving as the flagship hospital integration reference.
  • King Abdulaziz City for Science and TechnologystrategicStrategic or Co-development Partner · 1 December 2025Saudi Arabia's national research center partnering with GlycanAge to establish a Middle East laboratory for expanding diagnostic capabilities in the region.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

GlycanAge competitors and assessment

Company assessment

Emerging players

  • Fountain Life: Fountain Life operates premium longevity clinics offering advanced diagnostics (full-body MRI, blood biomarkers, AI-driven health assessments) and would be a relevant peer given GlycanAge's push to integrate glycan biomarkers into longevity clinic and hospital workflows as an embedded diagnostic layer.
  • Viome Life Sciences: Viome provides at-home microbiome and gene expression testing combined with personalized nutrition recommendations, overlapping with GlycanAge's D2C longevity testing and personalization model but using a different biological measurement modality (gut microbiome and mRNA rather than glycan biomarkers).

Direct peers

  • TruDiagnostic: TruDiagnostic offers epigenetic age testing and multi-omic biomarker analysis to both consumers and clinicians, with a strong focus on clinical research partnerships and longevity clinics — closely paralleling GlycanAge's consumer-plus-healthcare-provider model and biological age biomarker positioning.
  • InsideTracker: InsideTracker provides at-home blood-based biomarker testing with personalized longevity and performance recommendations, offering a comparable D2C subscription model and serving overlapping health-optimization consumers who want measurable biological age and healthspan insights.
  • ZOE: ZOE combines at-home blood, microbiome, and continuous glucose testing with personalized nutrition guidance for health-conscious consumers. It targets the same longevity/wellness segment as GlycanAge and competes on integrated biomarker testing plus lifestyle recommendations and 1:1 specialist interpretation.
  • Tally Health: Tally Health is a D2C biological age testing company offering at-home epigenetic age tests and longevity supplements, directly competing with GlycanAge in the consumer longevity testing category with overlapping target customers (biohackers, health-conscious consumers) and similar subscription pricing models.
  • Elysium Health: Elysium Health developed the Index at-home biological age test measuring cellular health via DNA methylation, and supplements (Basis). It competes directly with GlycanAge in the consumer biological age testing space and shares a similar science-led brand positioning backed by academic researchers.
  • Function Health: Function Health offers comprehensive at-home blood-based health testing (100+ biomarkers) with clinician review, targeting the same health-conscious consumer and longevity-conscious segment as GlycanAge, with a similar premium subscription model and at-home finger-prick collection approach.

Broad incumbents

  • Human Longevity Inc. Human Longevity Inc. provides comprehensive whole-genome sequencing, advanced imaging, and full-body diagnostics through premium executive health programs, competing with GlycanAge in the premium longevity diagnostics segment via a much broader (and higher-priced) multi-omics offering aimed at ultra-high-net-worth longevity clients.
  • Genentech Glycobiology Programs: Genentech (Roche) operates large-scale glycobiology and biopharma research programs and represents a broad incumbent in the glycobiology space whose commercial drug pipelines (e.g., glyco-engineered antibodies) demonstrate the broader pharmaceutical potential of IgG glycan science that GlycanAge's biomarker platform is built upon.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

GlycanAge social profiles

Digital presence

GlycanAge compliance and trust

Trust signal

Compliance1 record

GlycanAge financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GlycanAge leadership team

Management profile

Number of profiles

Profiles3 records

GlycanAge funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GlycanAge M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlycanAge

What does GlycanAge do?

GlycanAge provides a glycan-based biological age testing service that measures patterns of glycans attached to immunoglobulin G antibodies through an at-home finger-prick blood test. Results are delivered as personalized biological age reports combined with 1:1 longevity specialist consultations, with three primary service lines: personal-use test kits for consumers, clinical integration for healthcare providers and longevity clinics, and research services for academic institutions.

Is GlycanAge a public or private company?

GlycanAge is a private company. It is classified as venture growth investor backed and is currently operating.

When was GlycanAge founded?

GlycanAge was founded in 2016. It employs 11 to 50 people.

Where is GlycanAge based?

GlycanAge is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.

How does GlycanAge make money?

Three revenue lines are on record. Direct-to-Consumer Biological Age Testing is the primary driver. The others are healthcare Provider / Hospital Integration and research Collaborations.

Who are GlycanAge's main competitors?

Emerging players on record are Fountain Life and Viome Life Sciences. Direct peers are TruDiagnostic, InsideTracker, ZOE, Tally Health, Elysium Health and Function Health. Broad incumbents are Human Longevity Inc. and Genentech Glycobiology Programs.

Does GlycanAge have an API?

No public API is recorded for GlycanAge.

What industry is GlycanAge in?

GlycanAge's product category is Biological Age Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SeeNewsCroatian-founded GlycanAge expands biological-age testing to Abu DhabiGlycanAge, a Croatian-founded biotech startup, expanded its biological-age test to Abu Dhabi through a partnership with Unilabs. The test was introduced via Unilabs' healthcare network in collaboration with Hub71+ Life Sciences. The company also partnered with ExoEarth in Japan and raised 7.4 million euros in December 2025.Longevity.TechnologyGlycanAge teams up with Japan on aging scienceGlycanAge signed an MOU with ExoEarth to expand its glycan-based biological age test in Japan and run joint research. The partnership combines GlycanAge's inflammaging biomarkers with ExoEarth's exosome platform, with a longitudinal study pending regulatory review.EIN PresswireGlycanAge and ExoEarth Corp. Form Strategic Collaboration to Advance Biological Age Testing and Aging Research in JapanGlycanAge and ExoEarth Corp. announced a strategic collaboration to expand glycan-based biological age testing in Japan and pursue joint research on aging. The partnership, formalized via an MOU, combines GlycanAge's glycan biomarkers with ExoEarth's exosome biology to evaluate changes in biological-age and immune indicators linked to the EXOCURE program.PR NewswireStudy Validates Glycans as Aging Biomarker and Finds Therapeutic Plasma Exchange Yields Greatest ReductionA landmark study analyzing approximately 20,000 individuals across 42 studies has validated IgG glycans as an independently predictive biomarker of all-cause mortality and biological aging, with the research published as a preprint co-authored by investigators from GlycanAge, Circulate Health, the Buck Institute for Research on Aging, and more than 20 other institutions. The study found that therapeutic plasma exchange (TPE) produced the largest per-month reduction in glycan age at −0.4 years per month, surpassing hormone replacement therapy and caloric restriction among the three geroprotective interventions evaluated. GlycanAge announced an $8.7 million funding round in December 2025 to accelerate clinical adoption of glycan-based diagnostics, while Circulate Health continues advancing evidence-based TPE protocols through a growing network of partner longevity clinics in the United States.Longevity.TechnologyGlycans linked to aging – and possible reversalA large study of over 20,000 individuals across 42 studies found IgG glycan patterns track biological aging and predict mortality. Therapeutic plasma exchange reduced glycan age by about 0.4 years per month, suggesting the marker responds to intervention. The findings may help move longevity science toward measurable, evidence-based approaches.GlobeNewswireGlycobiology Research Report 2026 - Global Market Trends, Opportunities, and Forecasts, 2021-2025 & 2025-2031ResearchAndMarkets.com published a report projecting the global glycobiology market to grow from USD 1.87 billion in 2025 to USD 3.93 billion by 2031, representing a 13.18% CAGR driven by rising chronic disease prevalence and technological advancements in glycomics analysis. Key recent developments include Kyron: bio securing USD 6.0 million in May 2025 for glycan engineering in drug development, and GlycoNex: Inc. receiving PMDA approval in Japan on April 14, 2026 for a Phase 1 clinical trial of GNX1021, a glycan-focused antibody-drug conjugate for gastrointestinal tumors. The market faces headwinds from high research costs and complex glycan analysis techniques requiring specialized expertise, though continued funding from organizations such as GlycoNet (USD 4.5 million across 21 initiatives in December 2024) and GlycanAge (USD 8.7 million in December 2025) signals ongoing sector momentum.Longevity.TechnologyNew GlycanAge conference pushes inflammaging into careGlycanAge will host a conference in Dubrovnik, Croatia, to translate 25 years of inflammaging research into clinical practice. The company claims its glycan analysis can detect risk up to 10 years before conditions like diabetes or heart attack. The event aims to move inflammaging from theory to everyday medical care.Longevity.TechnologyGlycanAge to convene experts on inflammaging clinical applicationsGlycanAge will host a conference in Dubrovnik, Croatia, from 19 June to mark 25 years of inflammaging research, co-organized with Mayo Clinic. The company claims its glycan-based test has a measurement error of less than one year and is available in 64 markets through about 2,000 clinics.GlobeNewswireGlycanAge to Host Landmark Conference Focused on Practical Applications of Inflammaging ResearchGlycanAge, a UK-based biological age-testing company, is hosting a landmark conference in Dubrovnik, Croatia this June to mark 25 years of inflammaging research and promote the integration of chronic-inflammation testing into routine clinical practice, co-organized with Mayo Clinic as part of the ISABS conference series. The company's glycan-based blood test can detect disease-predictive patterns up to 10 years before symptoms appear, operates across 64 markets through approximately 2,000 clinics, and plans to expand its Asian coverage with a new laboratory facility in India.Longevity.TechnologyThe molecules you’ve been ignoring might be aging youGlycans, sugar molecules attached to proteins, are presented as biomarkers for biological age and inflammation. GlycanAge CEO Nikolina Lauc notes glycans shift with lifestyle, and a study showed exercise can initially increase biological age. GlycanAge will host an Inflammaging in Clinical Practice event on 20 June 2026.